Multiple Sclerosis and Related Disorders

Multiple Sclerosis and Related Disorders

AHSCT in multiple sclerosis 3:49
AHSCT in multiple sclerosis
Mark Freedman • 3 Mar 2021
REPAIR-MS: 31P-MRS imaging to assess the effects of CNM-Au8 in MS 3:30
REPAIR-MS: 31P-MRS imaging to assess the effects of CNM-Au8 in MS
Robert Glanzman • 1 Mar 2021
Extracellular vesicles as nanocarriers of apo-transferrin for CNS delivery 2:38
Extracellular vesicles as nanocarriers of apo-transferrin for CNS delivery
Jorge Correale • 5 Mar 2021
Predicting benign disease course in MS 2:33
Predicting benign disease course in MS
Mark Freedman • 3 Mar 2021
Leukocyte telomere length and disability in MS 2:11
Leukocyte telomere length and disability in MS
Jennifer Graves • 27 Feb 2021
Racial disparities in brain volumetric relationships with disability in MS 2:53
Racial disparities in brain volumetric relationships with disability in MS
Carlos Pérez • 25 Feb 2021
Novel B-cell targeting approaches in MS 2:23
Novel B-cell targeting approaches in MS
Amit Bar-Or • 25 Feb 2021
Moving the MS field forward: The search for reparative treatment 1:51
Moving the MS field forward: The search for reparative treatment
Rhonda Voskuhl • 25 Feb 2021
A case of dermatographism with ocrelizumab use in MS 0:56
A case of dermatographism with ocrelizumab use in MS
Jennifer Graves • 27 Feb 2021
COVID-19 severity in patients with MS 1:25
COVID-19 severity in patients with MS
Carlos Pérez • 25 Feb 2021
Markers of biological aging predict disability development in MS 1:41
Markers of biological aging predict disability development in MS
Jennifer Graves • 27 Feb 2021
MS across the lifespan: menopause and hormonal effects 2:06
MS across the lifespan: menopause and hormonal effects
Rhonda Voskuhl • 25 Feb 2021
B-cells in the pathogenesis of MS 1:48
B-cells in the pathogenesis of MS
Amit Bar-Or • 25 Feb 2021
Why is important to pay attention to cognition in multiple sclerosis? 3:20
Why is important to pay attention to cognition in multiple sclerosis?
Claire Riley • 26 Feb 2021
DMT use and clinical characteristics in MS by race and ethnicity 1:39
DMT use and clinical characteristics in MS by race and ethnicity
Carlos Pérez • 25 Feb 2021
Are COVID-19 vaccines safe and effective in the setting of MS DMTs? 4:06
Are COVID-19 vaccines safe and effective in the setting of MS DMTs?
Amit Bar-Or • 25 Feb 2021
The content of VJNeurology is intended for healthcare professionals